ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at [email protected]

Stock News for Merck (MRK)
DateTimeHeadline
01/12/201703:03:00Health Stocks Fall as Trump Slams Industry -- WSJ
01/10/201716:06:00Merck Receives FDA Acceptance of Supplemental Biologics License...
01/09/201708:00:00Incyte & Merck to Advance Clinical Development Program Investigating...
01/06/201708:00:00Merck to Participate at the 35th Annual J.P. Morgan Healthcare...
01/04/201715:05:00Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate--Update
01/04/201711:32:00Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate
01/03/201716:14:49Statement of Changes in Beneficial Ownership (4)
01/03/201716:14:24Statement of Changes in Beneficial Ownership (4)
01/03/201716:14:24Statement of Changes in Beneficial Ownership (4)
01/03/201716:14:24Statement of Changes in Beneficial Ownership (4)
01/03/201706:45:00Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings...
12/28/201603:02:00Ahead of the Tape: Trump Gives 'Dogs of the Dow' Pause -- WSJ
12/27/201616:28:00Donald Trump Dogs Dow Strategy -- Ahead of the Tape
12/19/201617:52:00Biogen Names New CEO -- Update
12/19/201607:00:00KEYTRUDA® (pembrolizumab) Approved as First Anti-PD-1 Therapy...
12/16/201607:26:00European Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA® (pem...
12/15/201618:40:00Gilead Sciences Ordered to Pay $2.5 Billion in Damages to Merck...
12/15/201618:36:00Gilead Sciences Ordered to Pay $2.5 Billion in Damages to Merck...
12/15/201618:05:00Court Orders Gilead to Pay Merck $2.54 Billion in Patent Case...
12/12/201607:00:00Interim Results from Phase 1b/2 Study Evaluating the Combination...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US